Patent ID: 8703121

Claim:
A method for maintaining cardiac function as measured by fractional shortening following myocardial infarction in a patient, the method comprising administering by injection to the ischemic myocardium of the patient a homogeneous population of cells in an amount effective to maintain cardiac function as measured by fractional shortening following myocardial infarction, wherein the homogeneous population of cells is isolated from human umbilical cord tissue substantially free of blood, does not express CD31, CD34, CD45, CD80, CD86, CD178, B7-H2, HLA-G, CD117, CD141 and HLA-DR, DP, DQ, does express CD10, CD13, CD44, CD73, CD90 PDGFr-alpha PD-L2 and HLA-A, B, C, has the potential for at least 40 doublings in culture, maintains a normal karyotype upon passaging, has the potential to express GATA4, and has increased expression of an endogenous gene encoding interleukin 8 and an endogenous gene encoding reticulon 1 relative to expression of an endogenous gene encoding interleukin 8 and an endogenous gene encoding reticulon 1 by a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.